Cotreatment with MS-20 and the anti-PD1 antibody significantly reduced the tumor growth by 40%-70% compared with that in the vehicle control and anti-PD1 antibody only treatment groups (Figure 1b). The gene discussed is PDCD1; the disease is neoplasm.